Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

PaperCitations, authors & open-access status

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 57 citations, 2015 year and gold oa status.

57
Citations
2015
Year
gold
OA Status

Related on ScholarIQ

Alexandros Sagkriotis
Author
PLoS ONE
Journal
Retinal Diseases and Treatments
Topic
Retinal Diseases and Treatments
Topic
Ocular Diseases and Behçet’s Syndrome
Topic
Ophthalmology and Visual Impairment Studies
Topic
470M+ articles · free account